X-Zell
Early, pain-free cancer detection.
X-ZELL™ is a global start-up specialising in rare cell detection technology. Backed by Y Combinator and various high-profile angel investors from around the globe – among them Gmail creator Paul Buchheit – X-ZELL™ has developed a world-first platform technology capable of isolating and visualizing rare and abnormal cells such as Circulating Endothelial Cells (CEC). X-ZELL™’s platform technology is based on four core modules covering the entire spectrum from blood processing through to cell analysis and reporting – with every step performed in-house using patented and proprietary technology. By combining the wisdom of 4,000 years of pathologic research with X-ZELL™’s own, cutting-edge technology, X-ZELL™ ensures robust results and maximum clinical utility across a broad range of medical applications – from research through to medication management, companions diagnostics, relapse control and diagnostic decision-making. More information on www.x-zell.com and @XZELLInc
- Website
- x-zell.com
- City
- Bangkok
- Country
- Thailand
- YC batch
- Winter 2015
- Team
- 19 people
- Stage
- Early stage
- AI-native
- No
Compiled from public sources with help from automated tools, including AI, so details can be out of date. How we build profiles.
Claim this profile
Free and instant: prove you run x-zell.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to X-Zell across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with X-Zell's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
